Gantenerumab

A4DAB124 | Neurological disorders | Phase-III

Target APP

Isotype / Subclass G1 / IgG1

Company

MorphoSys Chugai Pharmaceutical Roche

Clinical Status Phase-III

Format Whole mAb

Synonyms

R-1450 R1450 RG-1450 RG1450 RO-4909832 RO4909832

pH Formulation —

IMGT PubChem (135308536) PubChem (160704154) PubChem (178103515) PubChem (347911273) PubChem (464013589) PubChem (468575048) PubChem (472386067) PubChem (481155594) PubChem (505635349) Thera-SAbDab YAbS

Avg A4D Score

-0.6953

Score Range

-0.7 to -0.69

Structures

Structure ID	Source PDB	Seq. Identity	Avg. A4D Score	pH (Min Agg.)	pH (Max Agg.)	Score CDR	Score non-CDR
A4DAB124_5csz_A_B	5csz	100%	-0.6911	6.5	4.0	N/A	N/A
A4DAB124_5csz_H_L	5csz	100%	-0.6995	6.5	4.0	N/A	N/A

Gantenerumab

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2